Table 4. Multivariable analysis for mortality after the diagnosis of tuberculosis (TB) in RA patients according to therapeutic agents and the risk factors of mortality.
| Risk factors | Adjusted HR | 95% CI | p-value |
|---|---|---|---|
| RA/Non-RA | 1.25 | 1.11–1.40 | <0.001 |
| Therapeutic agents | |||
| csDMARDs | 1.00(reference) | - | - |
| Adalimumab | 0.22 | 0.07–0.69 | <0.01 |
| Etanercept | 1.08 | 0.76–1.54 | 0.669 |
| Rituximab | NA | NA | NA |
| Age at entry, years | |||
| 18–44 | 1.00(reference) | - | - |
| 45–64 | 2.36 | 1.70–3.28 | <0.001 |
| ≧65 | 4.31 | 3.07–6.05 | <0.001 |
| Gender | |||
| Female | 1.00(reference) | - | - |
| Male | 1.00 | 0.92–1.09 | 0.944 |
| Use of corticosteroids | |||
| Daily dose <5mg | 1.00 (reference) | - | - |
| Daily dose≧5mg | 1.69 | 1.47–1.95 | <0.001 |
| CCI | |||
| 0 | 1.00(reference) | - | - |
| 1 | 0.97 | 0.85–1.12 | 0.690 |
| 2 | 1.05 | 0.89–1.25 | 0.571 |
| ≧3 | 1.08 | 0.89–1.32 | 0.428 |
| Comarbidity | |||
| Diabetes mellitus | 1.16 | 1.00–1.34 | <0.05 |
| Liver cirrhosis | 1.05 | 0.88–1.25 | 0.617 |
| COPD | 0.91 | 0.80–1.04 | 0.176 |
| CKD | 1.10 | 0.77–1.59 | 0.593 |
csDMARDs: conventional synthetic disease-modifying anti-rheumatic drugs; HR: hazard ratio; 95%CI: 95% confidence interval; CCI: Charlson comorbidity index; COPD: chronic obstructive pulmonary disease; CKD: chronic kidney disease.
Adjusted HR estimated from multivariate Cox proportional hazard models comparing each biologic to csDMARDspropensity score adjusted for age, sex, and Charlson comorbidity index.